Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728361 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
A Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, sponsored by Dwight Owen.
- Active
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT03728361 is a Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma that is active but no longer recruiting, run by Dwight Owen. The registered enrollment target is 55 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03728361, a Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by Dwight Owen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and temozolomide may work better in treating patients with small-cell lung cancer and neuroendocrine cancer.
Conditions Studied
Interventions
- DRUG Temozolomide
- BIOLOGICAL Nivolumab
Study Locations (2)
Ohio
- Ohio State University Comprehensive Cancer Center-COHORT 1 - Columbus
- Ohio State University Comprehensive Cancer Center-COHORT 2 - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-12-31 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728361
The ClinicalTrials.gov registry entry for NCT03728361 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (69% lower). The listed sponsor is Dwight Owen, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT03728361 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03728361 about?
NCT03728361 is a clinical study titled "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer". This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab...
What is the current status of trial NCT03728361?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2018-12-31. Estimated completion is 2026-10-31.
What conditions does trial NCT03728361 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Recurrent Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03728361?
The interventions under investigation include: Temozolomide (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03728361?
This trial is sponsored by Dwight Owen, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03728361 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.